Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.1152W HIGH $34.48
Volume
246.35 K
Value Traded
1.93 M
Short % Float
3.8%
Days to Cover
4.8
-1.53%Week
-9.93%1 Month
-35.7%3 Month
-72.22%6 Month
+190.78%5 Year
+190.78%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
474.84 M
EPS (TTM)
-2.28
P/E Ratio
-
Ent. Value
1.31 B
Total Shares
61.59 M
Float Shares
47.06 M
Insiders
23.77%
Institutions
27.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
OCS Catalyst Timeline
Dated clinical, regulatory and corporate events for Oculis Holding AG
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oculis Holding AG
336Total events
11Upcoming
58Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationPrivosegtorPresentation
Phase 2 ACUITY data presentation at CNS Summit
acute optic neuritissource ↗
◆Oral PresentationPrivosegtorPresentation
CEO presentation on Privosegtor and PIONEER program at APOIS 2026 Congress
optic neuritissource ↗
▲Late-BreakerPrivosegtorPresentation
Late-breaking ACUITY biomarker data presented at 10th Joint ACTRIMS-ECTRIMS Meeting, MSToronto 2026
optic neuritissource ↗
▲Biomarker DataPrivosegtorClinical Data
New Phase 2 ACUITY biomarker data (NfL, GFAP) show reduced neuroaxonal injury vs placebo
optic neuritissource ↗
▲Enrollment CompletelicaminlimabTrial
Oculis completes randomization in PREDICT-1 registrational trial of Licaminlimab
TNFR1-mediated dry eye diseasesource ↗
●R&D DayPresentation
Oculis to sponsor Neuro-Ophthalmology Subspecialty Day at AAO 2026 Annual Meeting
●Oral PresentationlicaminlimabPresentation
Oculis CEO to present Licaminlimab at Eyecelerator @ AAO 2026
TNFR1-mediated dry eye diseasesource ↗
▲Partnership / LicenseCorporate
Oculis partners with National MS Society Campaign to End MS as Vision industry partner
multiple sclerosissource ↗
▲First Patient DosedPrivosegtorTrial
First patient treated in PIONEER-1 registrational trial
optic neuritissource ↗
▲Partnership / LicensePrivosegtorCorporate
Oculis signs asset purchase agreement with Accure Therapeutics for Privosegtor
▲FDA Feedback ReceivedPrivosegtorFDA Meeting
Positive FDA pre-IND feedback for Privosegtor in acute MS relapses
acute MS relapsesource ↗
●Trial InitiationPrivosegtorTrial
PIONEER-1 clinical site activation advancing as planned
optic neuritissource ↗
▲FDA Feedback ReceivedPrivosegtorFDA Meeting
FDA Division of Neurology provided guidance that no additional preclinical studies required ahead of IND submission for Privosegtor in acute MS relapses
acute multiple sclerosis relapsessource ↗
●Enrollment UpdatelicaminlimabTrial
PREDICT-1 enrollment >45% patients randomized, all planned sites activated
dry eye diseasesource ↗
▼Program DiscontinuationOCS-01FiledCorporate
Oculis does not plan to pursue FDA regulatory filing for OCS-01 in DME following DIAMOND topline results
diabetic macular edemasource ↗
▲Pre IND MeetingPrivosegtorFDA Meeting
FDA provided positive pre-IND feedback supporting regulatory pathway for Privosegtor in acute MS relapses
acute multiple sclerosis relapsessource ↗
◆Oral PresentationPrivosegtorPresentation
Presentation on Privosegtor in Optic Neuritis: From Discovery to PIONEER Registrational Trials at Clinical Trials at the Summit 2026
Optic Neuritissource ↗
◆Oral PresentationPresentation
Oculis management to present at 47th Annual Goldman Sachs Global Healthcare Conference
▲First Patient DosedlicaminlimabTrial
First patient randomized in PREDICT-1 registrational trial
Dry Eye Diseasesource ↗
◆Topline ReadoutOCS-01FiledClinical Data
Topline results from Phase 3 DIAMOND program for OCS-01 in DME expected in June 2026
diabetic macular edemasource ↗
◆Trial InitiationPrivosegtorTrial
PIONEER-3 trial initiation expected in mid-2026
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)source ↗
▼Topline ReadoutOCS-01FiledClinical Data
Topline results from Phase 3 DIAMOND-1 trial of OCS-01 in DME: primary endpoint not met
diabetic macular edemasource ↗
▼Primary Endpoint MissedOCS-01FiledClinical Data
DIAMOND trials failed to meet primary endpoint of mean change in BCVA at Week 52
diabetic macular edema (DME)source ↗
▼Program DiscontinuationOCS-01FiledCorporate
Oculis will not pursue FDA approval for OCS-01 in DME based on DIAMOND results
diabetic macular edemasource ↗
●Oral PresentationPresentation
Oculis to hold analyst and investor call on May 29, 2026 at 4:30 PM ET to discuss DIAMOND results and pipeline
●Pipeline PrioritizationCorporate
Oculis to focus development on Privosegtor PIONEER program and Licaminlimab PREDICT-1 trial
◆ATM ProgramCorporate
Board approved issuance of 5,750,400 shares as treasury shares for potential ATM sales
▲Last Patient Last VisitOCS-01FiledTrial
Last follow-up visit completed in both Phase 3 DIAMOND trials
Diabetic Macular Edemasource ↗
▲SPA AgreementPrivosegtorFDA Meeting
FDA Special Protocol Assessment (SPA) agreement for PIONEER-1 trial design
Optic Neuritissource ↗
▲Breakthrough Therapy DesignationPrivosegtorDesignation
Breakthrough Therapy designation granted by FDA for Privosegtor
optic neuritissource ↗
●Oral PresentationOCS-01FiledPresentation
DME AWARE Delphi study presented at COPHy and ARVO 2026
diabetic macular edemasource ↗
▲SPA AgreementPrivosegtorFDA Meeting
FDA SPA agreement for PIONEER-1 registrational trial in optic neuritis
optic neuritissource ↗
◆Oral PresentationPrivosegtorPresentation
Presentation of post-hoc analysis from Phase 2 ACUITY trial of Privosegtor in optic neuritis at ARVO
Optic Neuritissource ↗
●Poster PresentationPresentation
Latest findings from DME AWARE Delphi study presented at ARVO 2026 Annual Meeting
diabetic macular edemasource ↗
◆Oral PresentationPresentation
Presentation of final survey results from DME AWARE Delphi Study at ARVO
Diabetic Macular Edemasource ↗
◆Oral PresentationPresentation
CEO Riad Sherif presents corporate update at Eyecelerator @ ARVO 2026
◆Last Patient Last VisitOCS-01FiledTrial
Last patient visits completed for Phase 3 DIAMOND trials
diabetic macular edema (DME)source ↗
▲Last Patient Last VisitOCS-01FiledTrial
Last follow-up visit completed in Phase 3 DIAMOND program for OCS-01 in DME
diabetic macular edemasource ↗
◆Topline ReadoutOCS-01FiledClinical Data
Topline results from Phase 3 DIAMOND study of OCS-01 in diabetic macular edema expected in Q2 2026
diabetic macular edemasource ↗
▲Quarterly UpdateCorporate
Cash position of ~$278M as of March 31, 2026, providing runway into H2 2029
Past FDA Catalysts and PDUFA Decisions
How OCS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-02 | Privosegtor | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 21%
Micro Cap(rank 142 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Privosegtor Small moleculeNCT07623668 | Optic Neuritis | Phase 3 | RECRUITING | 210 | Dec 1, 2028 | ||||||
| licaminlimab Monoclonal antibodyNCT07548632 | Dry Eye Disease | Phase 2/3 | ACTIVE NOT_RECRUITING | 282 | Dec 1, 2026 | ||||||
| OCS-05+SoC administration Small moleculeCompletedNCT04762017 | Optic Neuritis | Phase 2 | COMPLETED | 36 | Sep 16, 2024 | ||||||
| OCS-01 Small moleculeCompletedNCT05147233 | Inflammation Eye Pain | Phase 3 | COMPLETED | 241 | Jul 3, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every OCS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Privosegtor BreakthroughOrphan | optic neuritis | Phase 2 | 2026-10-22 | significantly reduced plasma neurofilament light chain and glial fibrillary acidic protein levels compared to placebo; 18-letter gains in low-contrast visual acuity at Month 3 vs steroid alone; NfL levels remained stable in the Privosegtor group through Month 6; GFAP levels remained below baseline in the Privosegtor group over the same periodRead More | Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic NeuritisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in OCS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.2 % (-33.3 %) | 11.22 M | 808.83 K | 63.79% ( 315.00 K) |
Ownership Trends
OCS Short Interest
Shares sold short, counted twice a month.
3.8%
Short % of Float
of tradable shares sold short
1.8M
Shares Sold Short
+0.9% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
372.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OCS ranks across every disease it competes in
Competitive Position is a premium feature
See how OCS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOCS News
OCS▼ -6.7%on this news
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Oculis appointed Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to advance its lead asset, Privosegtor, through the PIONEER program. Tackenberg will focus on expanding its applications in acute multiple sclerosis and other neurological conditions. The company also welcomed Aaron Tansy as Vice President, Development Franchise Head, Neurology, enhancing its expertise in clinical development.
Read more →OCSOculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Oculis announced positive findings from the Phase 2 ACUITY trial of Privosegtor, indicating its potential as a first-in-class neuroprotective treatment for optic neuritis. The company will present these findings at the upcoming APOIS Congress and CNS Summit. Privosegtor has received Breakthrough Therapy and PRIME designations, supporting its ongoing development.
Read more →OCSOculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Oculis announced positive Phase 2 ACUITY trial results for Privosegtor in optic neuritis. The treatment significantly reduced plasma neurofilament light chain and glial fibrillary acidic protein levels compared to placebo. These findings align with previously reported functional improvements in visual acuity and retinal preservation, supporting Privosegtor's potential as a neuroprotective therapy.
Read more →OCSOculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Oculis Holding AG announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be presented at the 10th Joint ACTRIMS-ECTRIMS Meeting. The data evaluates plasma NfL and GFAP as biomarkers for neuroaxonal injury in patients with acute optic neuritis. The findings aim to enhance understanding of neuroprotection mechanisms and the potential of Privosegtor in treating optic neuritis.
Read more →OCSOculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Oculis has completed randomization in the PREDICT-1 trial for Licaminlimab, a potential first-in-class treatment for TNFR1-mediated dry eye disease. The trial aims to evaluate the efficacy of Licaminlimab in patients with a specific TNFR1 genotype. Topline results are expected by the end of 2026, following promising outcomes in earlier studies. This precision medicine approach could significantly improve treatment for a large patient population.
Read more →OCSOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis has published a notification regarding the vesting and settlement of Restricted Stock Units (RSUs) for a member of its Executive Committee and Board of Directors. This transaction, involving Riad Sherif, took place on October 5, 2026. The notification underscores the company's commitment to transparency in its managerial activities.
Read more →OCSOculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Oculis Holding AG will present Licaminlimab at Eyecelerator @ AAO 2026, showcasing its potential in treating TNFR1-mediated dry eye disease. The company is also sponsoring the Neuro-Ophthalmology Subspecialty Day at the AAO Annual Meeting. The upcoming topline results from the PREDICT-1 trial are anticipated by year-end, which could significantly impact treatment approaches.
Read more →OCS▼ -6.2%on this news
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis Holding AG has partnered with the National Multiple Sclerosis Society to launch a five-year campaign aimed at accelerating research and improving care for multiple sclerosis (MS) patients. This collaboration will focus on the development of Privosegtor, a potential neuroprotective therapy for optic neuritis and acute MS relapses. The campaign includes various programs to engage stakeholders in the MS community.
Read more →OCS▼ -6.2%on this newsshared move
Oculis Announces Resignation of Lionel Carnot from Board of Directors
Oculis Holding AG announced the resignation of director Lionel Carnot from its Board of Directors, effective immediately. Carnot has served since 2017 and expressed gratitude for his time with the company. His departure is a personal decision and not due to any disagreements. The board will now consist of eight members as Oculis seeks a successor.
Read more →OCSFirst Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG has initiated the PIONEER-1 registrational trial, marking a significant milestone in evaluating Privosegtor for optic neuritis. This trial follows positive Phase 2 data and aims to establish Privosegtor as a potential neuroprotective therapy. The study will assess the drug's efficacy and safety, with promising implications for broader neurological applications.
Read more →OCSOculis acquires development and commercial rights to Privosegtor
Oculis has successfully acquired the development and commercial rights to Privosegtor. This acquisition is expected to strengthen Oculis's product offerings and market presence. The move indicates a strategic expansion aimed at enhancing their portfolio and potentially increasing revenue opportunities.
Read more →OCSOculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Oculis has signed an asset purchase agreement with Accure Therapeutics to acquire worldwide rights to Privosegtor, a promising neuroprotective therapy. This strategic move allows Oculis to terminate its existing license agreement with Accure, enhancing its potential for economic upside. The acquisition includes an upfront payment and shares, with expected closings in early 2027. Privosegtor is currently advancing through key regulatory trials.
Read more →OCSOculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis reported its Q2 2026 financial results, highlighting progress in its neuro-ophthalmology pivot, particularly with Privosegtor in the PIONEER program and Licaminlimab in the PREDICT-1 trial. The company has received positive FDA feedback and is well-funded to continue its development efforts. However, it has decided not to pursue an FDA filing for OCS-01 in diabetic macular edema.
Read more →OCSFDA feedback supports new testing path for therapy in MS relapses
The FDA has provided feedback that supports a new testing pathway for a therapy aimed at treating relapses in multiple sclerosis (MS). This development is seen as a positive step towards enhancing treatment options for patients. The feedback may facilitate further clinical testing and regulatory processes for the therapy.
Read more →OCS▲ +5.1%on this newsshared move
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis announced positive FDA pre-IND feedback for Privosegtor, a novel neuroprotective candidate aimed at treating acute multiple sclerosis relapses. The FDA confirmed that existing data can be used for an IND application, which is planned for submission in Q4 2026. This development supports Oculis's strategy to address significant unmet needs in neuro-ophthalmology.
Read more →OCSOculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG will participate in the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company plans to discuss its late-stage portfolio, including Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy designation, and Licaminlimab, a topical anti-TNFα for dry eye disease. The conference will also allow for one-on-one meetings with investors.
Read more →About Oculis Holding AG
BIOPHARMAWATCH ELITE PLUS
Trade the next OCS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime